Skip to main
  1. Stocks
  2. MiniMed Group Inc
  3. Forecast
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 31%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group is viewed favorably because its 2026 IPO and near-complete separation from Medtronic should remove technical overhangs and let fundamentals show through, while the company’s clean balance sheet and stand-alone focus support faster execution. Its unique “full-stack” diabetes platform—traditional pumps, CGMs, smart pens, and a proprietary pharmacy—helps deepen recurring revenue, improve retention, and capture growth in underpenetrated T1/T2 intensive-insulin markets, where penetration remains low. With new products already launching or nearing launch, revenue is modeled to grow from $3,102M in FY26 to about $4,097M by FY29E, while adjusted EBITDA margin expands from 15.5% to 20.8%.

Bears say

Minimed Group is burdened by a temporary but significant ownership overhang, since Medtronic still retains about 90% of shares after the March 2026 IPO, keeping trading dynamics and investor perception tied to Medtronic rather than a clean standalone profile. The company also faces meaningful execution risk from competitive pressure, limited traction in new product launches, and the possibility that existing patients switch to rival pumps, while a delay to the planned summer 2027 FIT patch pump launch could cede share to competing systems. In addition, dependence on Abbott for its exclusive CGM supply, potential pharmacy-channel economics challenges, GLP-1-related slowdowns in Type 2 adoption, and ongoing transition-service, royalty, and margin headwinds all point to a constrained growth and profitability ramp.

MMED has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 31% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

MMED Analyst Forecast & Price Prediction

Get the latest MMED stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MMED

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 13 analysts, MMED has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


MMED Analyst Forecast & Price Prediction

Get the latest MMED stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MMED

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MMED stock data and trends